Loading...
Subcutaneous apomorphine infusion for Parkinson disease (PD) has been tested only in open-label studies. Preliminary data suggested that it may be effective in improving dopaminergic “off” time. Now, researchers have conducted a randomized, placebo-controlled, multicenter, double-blind, manufacturer-funded study of 106 PD patients diagnosed at least 3 years previously who had persistent motor fluctuations despite medication optimization. Participants received either 3 to 8 mg/hour of apomorphine subcutaneously infused or a placebo saline infusion for 12 weeks. The flow rate as well as other PD medications could be adjusted for the first 4 weeks of therapy. The primary outcome variable was the change in daily dopaminergic “off” time, tracked…